FHTX (Foghorn Therapeutics) Accounts Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
67 GF Score
Price $6.68
GF Value $5.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Accounts Receivable?

Foghorn Therapeutics FHTX -2.19% 67 Accounts Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Foghorn Therapeutics's accounts receivables for the quarter that ended in Jun. 2026 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Foghorn Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Foghorn Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-1.99.

Foghorn Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Foghorn Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/16.072*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Foghorn Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Foghorn Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(167.582+0.75 * 0+0.5 * 0-284.434
-0-0)/58.714
=-1.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Foghorn Therapeutics Accounts Receivable Related Terms

Foghorn Therapeutics Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Foghorn Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics Accounts Receivable Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Receivable
Get a 7-Day Free Trial 300.00 0.00 0.00 0.00 0.00

Foghorn Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FHTX
67GF Score
Foghorn Therapeutics Inc FHTX
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foghorn Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.00 Mil mean?
Foghorn Therapeutics (FHTX) has a Accounts Receivable of $0.00 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Foghorn Therapeutics and its competitors.
Is Foghorn Therapeutics' Accounts Receivable too high?
Foghorn Therapeutics' current Accounts Receivable is $0.00 Mil. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Accounts Receivable compare to NWBO and FATE?
Foghorn Therapeutics' Accounts Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Foghorn Therapeutics and its competitors. Foghorn Therapeutics's current Accounts Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.68 — trading 25.5% above its estimated fair value. The current Accounts Receivable is $0.00 Mil. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Accounts Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued. The current stock price of $6.68 is trading 25.5% above its estimated GF Value™ of $5.32. GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.

Key valuation signals for FHTX:

  • Accounts Receivable: $0.00 Mil
  • GF Value™: $5.32 vs. price of $6.68 (25.5% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score

Get the complete analysis for FHTX

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.68
Price
$5.32
GF Value